John DeYoung
DirectoratAllogene Therapeutics· In proxies 2023–2025
John DeYoung sits on 1 public board.
Boards1
- Allogene TherapeuticsDirector · 7 yr on the boardIndependentCompensation, International and Business Development Oversight—Paid as an executive
Board seats come from each company's latest proxy statement.
Experience
- Allogene TherapeuticsPublic company · 3 yr
- Director2023 – Present · 3 yrStock in role -77%
Roles come from the proxy statements of each company.
Activity
No new filings about this person in the feed.
Two people shown as one, or a wrong number?